Art

J-GLOBAL ID：201102273317153984   Reference number：11A0861134

Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma

転移性腎細胞癌患者におけるスニチニブ標的療法とファーストライン療法としてのサイトカインによる無進行及び全生存の予後因子

Author (8)： PATIL S. (Memorial Sloan-Kettering Cancer Center, NY, USA) ,  FIGLIN R. A. (City of Hope Comprehensive Cancer Center, CA) ,  HUTSON T. E. (Baylor Sammons Cancer Center-Texas Oncology, TX) ,  MICHAELSON M. D. (Massachusetts General Hospital Cancer Center, MA, USA) ,  NEGRIER S. (Centre Leon Berard, Lyon, FRA) ,  KIM S. T. (Pfizer Oncology, CA) ,  HUANG X. (Pfizer Oncology, CA) ,  MOTZER R. J. (Memorial Sloan-Kettering Cancer Center, NY, USA)
Material： Annals of Oncology  (Ann Oncol)
Volume： 22  Issue： 2  Page： 295-300  Publication year： Feb. 2011 
JST Material Number： W0107A  ISSN： 0923-7534  CODEN： ANONE2  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： *renal cell carcinoma ,...
Semi thesaurus term： IFN-alpha ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=11A0861134&from=J-GLOBAL&jstjournalNo=W0107A") }}

JST classification (4)： Urogenital tumors(=neoplasms)  (GM04000S) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C) ,  Cytokines  (EB08090G)

Substance index (1)： Sunitinib

Reference (13)：

• Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296.
• Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832-841.
• Molina AM, Motzer RJ. Current algorithms and prognostic factors in the treatment of metastatic renal cell carcinoma. Clin Genitourin Cancer 2008; 6: s7-s13.
• Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281.
• Motzer RJ, Hutson TE, Tomczak P et al. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590.

Terms in the title (8)： 転移性腎細胞癌 ,  患者 ,  スニチニブ ,  標的療法 ,  療法 ,  サイトカイン ,  生存 ,  予後因子